News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
512,716 Results
Type
Article (43967)
Company Profile (124)
Press Release (468625)
Section
Business (144467)
Career Advice (2369)
Deals (27862)
Drug Delivery (99)
Drug Development (67659)
Employer Resources (147)
FDA (15490)
Job Trends (11905)
News (262606)
Policy (29535)
Tag
Academia (2281)
Africa (666)
Alliances (35649)
Alzheimer's disease (1215)
Approvals (15402)
Arizona (125)
Artificial intelligence (77)
Asia (30280)
Australia (5285)
Bankruptcy (299)
Best Places to Work (8936)
Biosimilars (70)
Biotechnology (76)
Breast cancer (71)
C2C Services and Suppliers (51907)
California (1828)
Canada (748)
Cancer (604)
Career advice (1976)
Cell therapy (154)
China (120)
Clinical research (52970)
Collaboration (167)
Colorado (71)
Compensation (111)
Connecticut (87)
COVID-19 (2511)
Cystic fibrosis (73)
Data (437)
Diabetes (99)
Diagnostics (4978)
Drug pricing (91)
Earnings (56061)
Employer resources (132)
Europe (73372)
Events (73387)
Executive appointments (155)
FDA (15781)
Florida (278)
Funding (156)
Gene therapy (114)
GLP-1 (593)
Government (3775)
Healthcare (14649)
Hotbed/Location (337079)
Illinois (201)
Indiana (120)
Infectious disease (2553)
Inflammatory bowel disease (87)
Interviews (442)
IPO (13722)
Job creations (3148)
Job search strategy (1656)
Kansas (75)
Layoffs (436)
Legal (6882)
Lung cancer (124)
Manufacturing (114)
Maryland (398)
Massachusetts (1507)
Medical device (10969)
Medtech (10972)
Mergers & acquisitions (14071)
Metabolic disorders (321)
Michigan (101)
Minnesota (176)
Neuroscience (1401)
New Jersey (563)
New York (569)
NextGen Class of 2024 (4954)
Non-profit (3152)
North Carolina (551)
Northern California (832)
Obesity (197)
Ohio (90)
Opinion (179)
Patents (78)
Pennsylvania (550)
People (41509)
Phase I (15741)
Phase II (22902)
Phase III (18939)
Pipeline (140)
Policy (73)
Postmarket research (2192)
Preclinical (6342)
Radiopharmaceuticals (196)
Rare diseases (152)
Real estate (4242)
Regulatory (19960)
Research institute (2045)
Resumes & cover letters (398)
South America (1030)
Southern California (747)
Startups (2734)
Texas (234)
United States (8067)
Vaccines (560)
Washington State (237)
Weight loss (179)
Date
Last 7 days (602)
Last 30 days (2296)
Last 365 days (32232)
2024 (24229)
2023 (34982)
2022 (45058)
2021 (48501)
2020 (45518)
2019 (36222)
2018 (27410)
2017 (27817)
2016 (25811)
2015 (27977)
2014 (21774)
2013 (17794)
2012 (18963)
2011 (19381)
2010 (17504)
512,716 Results for "pharmamar s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Psychosis: The Other Big Alzheimer’s Therapeutic Target
While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.
March 27, 2024
·
7 min read
·
Sruthi S. Balakrishnan
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and
BioSpace
heads to Meeting on the Mesa.
October 2, 2024
·
1 min read
·
Heather McKenzie
Parkinson’s disease
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
September 27, 2024
·
2 min read
·
Tristan Manalac
Drug Development
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
PharmaMar and partner Jazz Pharmaceuticals plc announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® for the treatment of patients with relapsed small cell lung cancer.
December 13, 2021
·
11 min read
Regulatory
Novo Secures EU Panel’s Backing for Cardiovascular Use of Wegovy
With Thursday’s positive opinion from the Committee for Medicinal Products for Human Use, the matter now heads to the European Commission which will have the final say on whether Wegovy’s label will be updated.
September 20, 2024
·
2 min read
·
Tristan Manalac
Regulatory
AstraZeneca’s Imfinzi Scores Lung Cancer Wins With FDA’s NSCLC Approval, SCLC Priority Review
Imfinzi’s perioperative approval comes after both the FDA’s staffers and a panel of external experts expressed concerns about overtreatment when using the PD-L1 blocker both before and after surgery.
August 16, 2024
·
2 min read
·
Tristan Manalac
Regulatory
EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s
The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.
July 26, 2024
·
2 min read
·
Tyler Patchen
Immunology and inflammation
GSK Builds Nucala’s COPD Case With Phase III Win
If approved in chronic obstructive pulmonary disease, Nucala will compete with Verona’s Ohtuvayre and—pending a potential approval later this month—Sanofi and Regeneron’s blockbuster Dupixent.
September 6, 2024
·
2 min read
·
Tristan Manalac
Podcast
Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated approval for schizophrenia.
September 25, 2024
·
1 min read
·
Heather McKenzie
Sickle Cell Disease
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
September 27, 2024
·
7 min read
·
Annalee Armstrong
1 of 51,272
Next
